Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction), neprilysin inhibition reduced the risk of cardiovascular death and total hospitalizations by 13%, improved KCCQ by 1.0 points, and had no overall effect on the EuroQol Visual Analog Scale.3,9”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Self-citationThe perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Self-citationSolomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationPhenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Research works printed but not linked: 1
- Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and sur- vival times. Appl Stat 2006; 55: 31-9.
Cited by
Items 401–500 of 1,000
Ferreira, J. P., Claggett, B. L., Liu, J., Desai, A. S., Pfeffer, M. A., Anand, I. S., van Veldhuisen, D. J., Køber, L., Cleland, J. G. F., Rouleau, J. L., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2134 · Cited by 37
Self-citationPatient-Reported Outcomes in Cardiovascular Trials
Creber, R. M., Spadaccio, C., Dimagli, A., Myers, A., Taylor, B., & Fremes, S. E. (2021) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.04.006 · Cited by 48
Fonseca, A. F., Lahoz, R., Proudfoot, C., Corda, S., Loefroth, E., Jackson, J., Cotton, S. E., & Studer, R. L. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s312200 · Cited by 37
Heinzel, F. R., & Shah, S. J. (2022) · Herz · doi:10.1007/s00059-022-05124-8 · Cited by 38
“Phase3HFpEFclinical trials suchasTOPCAT and PARAGON have shown that patients with LVEF >65%, especially men, do not respond favorably [39, 56] and are particularly resistant to conventional HF therapeutics.”
MethodSelf-citationBrittain, E. L., Thenappan, T., Huston, J., Agrawal, V., Lai, Y., Dixon, D., Ryan, J. J., Lewis, E. F., Redfield, M. M., Shah, S. J., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001079 · Cited by 36
Self-citationChatur, S., Vaduganathan, M., Peikert, A., Claggett, B. L., McCausland, F. R., Skali, H., Pfeffer, M. A., Beldhuis, I. E., Køber, L., Seferovic, P. M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2638 · Cited by 36
Self-citationOlivotto, I., Udelson, J. E., Pieroni, M., & Rapezzi, C. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac764 · Cited by 38
Tromp, J., Kosiborod, M., Angermann, C. E., Collins, S. P., Teerlink, J. R., Ponikowski, P. P., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3218 · Cited by 40
Schauer, A., Adams, V., Augstein, A., Jannasch, A., Draskowski, R., Kirchhoff, V., Goto, K., Mittag, J., Galli, R., Männel, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073570 · Cited by 35
“Sac/Val has been shown to exert beneficial effects at least in certain subgroups [8,14,15].”
BackgroundInfluentialEpidemiological and clinical boundaries of heart failure with preserved ejection fraction
Gentile, F., Ghionzoli, N., Borrelli, C., Vergaro, G., Pastore, M. C., Cameli, M., Emdin, M., Passino, C., & Giannoni, A. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab077 · Cited by 42
Current Prevalence, Incidence, and Outcomes of Heart Failure with Preserved Ejection Fraction
Cho, D.-H., & Yoo, B. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.03.002 · Cited by 38
Recent advances in pharmacological treatment of heart failure
Iacoviello, M., Palazzuoli, A., & Gronda, E. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13624 · Cited by 39
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF
Gori, M., Senni, M., Claggett, B. L., Liu, J., Maggioni, A. P., Zile, M. R., PRESCOTT, M. F., van Veldhuisen, D. J., Zannad, F. M., Pieske, B. M., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.04.009 · Cited by 35
Self-citationNeprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity
Sobiborowicz, A., Kamińska, K., & Cudnoch‐Jędrzejewska, A. (2023) · Cancers · doi:10.3390/cancers15010312 · Cited by 35
“As for the patients with HF with preserved EF (HFpEF), a large multicenter clinical trial PARAGON-HF comparing ARNi to ARB monotherapy failed to demonstrate differences in the risk of cardiovascular death or total hospitalizations, and thus, the role of ARNi in the treatment of HFpEF remains uncertain [85].”
BackgroundCastiglione, V., Gentile, F., Ghionzoli, N., Chiriacò, M., Panichella, G., Aimo, A., Vergaro, G., Giannoni, A., Passino, C., & Emdin, M. (2023) · Cardiac failure review · doi:10.15420/cfr.2022.23 · Cited by 37
“55 As for non-pharmacological neuromodulation therapies, current evidence from clinical studies is still limited in patients with HFpEF, so international HF guidelines do not provide specific recommendations for their use.”
Kresoja, K., Unterhuber, M., Wachter, R., Rommel, K., Besler, C., Shah, S. J., Thiele, H., Edelmann, F., & Lurz, P. C. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104795 · Cited by 35
Self-citationJhund, P. S., Claggett, B. L., Talebi, A., Butt, J. H., Gasparyan, S. B., Wei, L., McCaw, Z. R., Wilderäng, U., Bengtsson, O., Desai, A. S., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.0711 · Cited by 37
Self-citationOstrominski, J. W., Lassen, M. C. H., Butt, J. H., Claggett, B. L., Anand, I. S., Desai, A. S., Jhund, P. S., Lam, C. S. P., Pfeffer, M. A., Pitt, B., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.012 · Cited by 34
Self-citationThe year in cardiology: heart failure
Cleland, J. G. F., Lyon, A. R., McDonagh, T. A., & McMurray, J. J. V. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz949 · Cited by 37
“Reproduced with permission from ref.(91) 1238 J.”
Self-citationARNI in Cardiovascular Disease: Current Evidence and Future Perspectives
Kuchulakanti, P. K. (2020) · Future Cardiology · doi:10.2217/fca-2019-0089 · Cited by 34
Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event
Schmidli, H., Roger, J., & Akacha, M. (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2021.1895883 · Cited by 38
“The PARAGON-HF trial (Solomon et al. 2019) in patients with CHF is an example where all recurrent HHF and mortality information was used in the primary assessment of the treatment effect, moving away from the traditional time-to-event endpoint.”
MethodEndocrine system dysfunction and chronic heart failure: a clinical perspective
Lisco, G., Giagulli, V. A., Iovino, M., Zupo, R., Guastamacchia, E., Pergola, G. D., Iacoviello, M., & Triggiani, V. (2021) · Endocrine · doi:10.1007/s12020-021-02912-w · Cited by 37
“ventricle ejection fraction (CHF with reduced or mildly reduced ejection fraction) [31, 32].”
BackgroundKagami, K., Obokata, M., Harada, T., Kato, T., Wada, N., Adachi, T. K., & Ishii, H. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.026009 · Cited by 35
Medical Therapy for Functional Mitral Regurgitation
Milwidsky, A., Mathai, S. V., Topilsky, Y., & Jorde, U. P. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.122.009689 · Cited by 38
Chatur, S., Claggett, B. L., Vardeny, O., Jering, K., Desai, A. S., Pfeffer, M. A., Lefkowitz, M. P., McMurray, J. J. V., Solomon, S. D., & Vaduganathan, M. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2703 · Cited by 34
Self-citationTsukamoto, S., Uehara, T., Azushima, K., Wakui, H., & Tamura, K. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029565 · Cited by 36
Health‐related quality of life outcomes in PARAGON‐HF
Chandra, A., Polanczyk, C. A., Claggett, B. L., Vaduganathan, M., Packer, M., Lefkowitz, M. P., Rouleau, J. L., Liu, J., Shi, V. C., Schwende, H., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2738 · Cited by 33
Self-citationSGLT2 inhibitors: an evidence-based update on cardiovascular implications
Forzano, I., Wilson, S. M., Lombardi, A., Jankauskas, S. S., Kansakar, U., Mone, P., Varzideh, F., & Santulli, G. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2263354 · Cited by 34
“Especially thrilling is the interest of the scientific community in gliflozins to treat HFpEF, a clinical syndrome for which there is not a universally accepted therapy, lacking evidence for a specific disease-modifying medication [44–48].”
BackgroundKondo, T., Campbell, R. T., Jhund, P. S., Anand, I. S., Carson, P. E., Lam, C. S. P., Shah, S. J., Vaduganathan, M., Zannad, F. M., Zile, M. R., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.027 · Cited by 35
Self-citationCardiovascular and non‐renal complications of chronic kidney disease: Managing risk
Rossing, P. R., Hansen, T. W., & Kümler, T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15747 · Cited by 36
“42 For ARNIs and steroidal MRAs, results have been borderline 41,48,49 but, as mentioned, the nonsteroidal MRA finerenone is currently being studied in this population and is expected to report in 2024 (clinicaltrials.gov NCT04435626).”
Nguyen, D. V., Le, T. N., Truong, B. Q., & Nguyen, H. T. T. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3454 · Cited by 34
Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials
Patel, R. B., ter Maaten, J. M., Ferreira, J. P., Causland, F. R. M., Shah, S. J., Rossignol, P., Solomon, S. D., Vaduganathan, M., Packer, M., Thompson, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.049514 · Cited by 37
Self-citationAroor, A. R., Mummidi, S., López-Alvarenga, J. C., Das, N. A., Habibi, J., Jia, G., Lastra, G., Chandrasekar, B., & DeMarco, V. G. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01270-1 · Cited by 34
“Simmonds SJ, et al. Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding.”
BackgroundInfluentialVaduganathan, M., Piccini, J. P., Camm, A. J., Crijns, H. J. G. M., Anker, S. D., Butler, J., Stewart, J. A., Braceras, R., Albuquerque, A. P. A., Wieloch, M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2487 · Cited by 33
Kario, K., & Williams, B. (2022) · Hypertension Research · doi:10.1038/s41440-022-00923-2 · Cited by 34
“The effects of sacubitril/valsartan in patients with HFpEF were investigated in the PARAGON-HF trial [8].”
BackgroundMethodTransvenous Right Greater Splanchnic Nerve Ablation in Heart Failure and Preserved Ejection Fraction
Fudim, M., Zirakashvili, T., Shaburishvili, N., Shaishmelashvili, G., Sievert, H., Sievert, K., Reddy, V. Y., Engelman, Z. J., Burkhoff, D., Shaburishvili, T., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.05.009 · Cited by 35
Self-citationBlood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Selvaraj, S., Vaduganathan, M., Claggett, B. L., Miao, Z. M., Fang, J. C., Vardeny, O., Desai, A. S., Shah, S. J., Lam, C. S. P., Martínez, F. A., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.09.002 · Cited by 35
Self-citationRecent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Comprehensive Review
Kim, J. A., Wu, L., Rodriguez, M., Lentine, K. L., Virk, H. U. H., Hachem, K. E., Lerma, E. V., Kiernan, M. S., Rangaswami, J., & Krittanawong, C. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101509 · Cited by 34
Morgen, C. S., Haase, C. L., Oral, T. K., Schnecke, V., Varbo, A., & Borlaug, B. A. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.07.008 · Cited by 32
Lin, X., Wu, G., Wang, S., & Huang, J. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10362-x · Cited by 34
Gharagozloo, K., Mehdizadeh, M., Heckman, G. A., Rose, R. A., Howlett, J. G., Howlett, S. E., & Nattel, S. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.006 · Cited by 47
Systolic Blood Pressure and Pulse Pressure in Heart Failure
Lu, H. Y., Kondo, T., Claggett, B. L., Vaduganathan, M., Neuen, B. L., Beldhuis, I. E., Jhund, P. S., Causland, F. R. M., Anand, I. S., Pfeffer, M. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.007 · Cited by 32
Self-citationCoppi, F., Pagnoni, G., Grossule, F., Nassar, A., Maini, A., Masaracchia, G., Sbarra, F., Battigaglia, E., Maggio, E., Aschieri, D., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12060213 · Cited by 40
“In the PARAGON-HF trial, which included 4822 patients with heart failure with EF > 45% and in NYHA class II-IV, ARNI was not shown to significantly reduce the primary endpoint (mortality from cardiovascular causes or hospitalization for heart failure), compared to valsartan alone [85].”
Epelde, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144820 · Cited by 40
“These phenotypes—often defined by demographic factors, comorbidity patterns, hemodynamic features, or biomarker profiles—demonstrate varying clinical trajectories and differential responses to therapy [13,14].”
What Is Cardiometabolic HFpEF and How Can We Study it Preclinically?
Daou, D., Tong, D., Schiattarella, G. G., Gillette, T. G., & Hill, J. A. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.04.009 · Cited by 37
Kautzky‐Willer, A., Harreiter, J., Abrahamian, H., Weitgasser, R., Fasching, P., Hoppichler, F., & Lechleitner, M. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-018-1421-1 · Cited by 36
Acutely decompensated versus acute heart failure: two different entities
Xanthopoulos, A. V., Butler, J., Parissis, J., Polyzogopoulou, E., Skoularigis, J. S., & Triposkiadis, F. K. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09894-y · Cited by 39
Kashiwagi, A., Araki, S., & Maegawa, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13329 · Cited by 33
Range of adiposity and cardiorenal syndrome
Pazos, F. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i8.322 · Cited by 35
Current Modulation of Guanylate Cyclase Pathway Activity—Mechanism and Clinical Implications
Grześk, G., & Nowaczyk, A. (2021) · Molecules · doi:10.3390/molecules26113418 · Cited by 32
“Meta-analysis from clinical trials suggest the presence of a beneficial effect only in patients with reduced EF, whereas in patients with EF > 45%, the effect is not significant [65,66].”
MethodYeh, J., Yue, Y., Chu, Y., Huang, C., Yang, C., Chiang, J. Y., Yip, H., & Guo, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112244 · Cited by 32
Peverill, R. E. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203079 · Cited by 34
Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction
Omote, K., & Borlaug, B. A. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0795 · Cited by 38
Peikert, A., Vaduganathan, M., Causland, F. R. M., Claggett, B. L., Chatur, S., Packer, M., Pfeffer, M. A., Zannad, F. M., Lefkowitz, M. P., Pieske, B. M., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2450 · Cited by 35
Self-citationCardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist
Palanisamy, S., Hernandez, M. R. F., Chang, T. I., & Mahaffey, K. W. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00269-3 · Cited by 37
Mehran, R., Steg, P. G., Pfeffer, M. A., Jering, K., Claggett, B. L., Lewis, E. F., Granger, C. B., Køber, L., Maggioni, A. P., Mann, D. L., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060841 · Cited by 37
Self-citationChatur, S., Claggett, B. L., McCausland, F. R., Rouleau, J. L., Zile, M. R., Packer, M., Pfeffer, M. A., Lefkowitz, M. P., McMurray, J. J. V., Solomon, S. D., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.02.009 · Cited by 32
“Sacubitril/valsartan significantly reduced the risk of cardiovascular death or HF hospitalization in PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitors with Angiotensin-Converting Enzyme Inhibitors to Determine Impact on Global Mortality and Morbidity in Heart Failure)(6) and led to a mo…”
BackgroundMethodSelf-citationShi, Y., Yang, C. G., Qiao, W., Liu, Y. C., Liu, S. Y., & Dong, G. J. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176170 · Cited by 34
Hypertensive heart disease in older patients: considerations for clinical practice
Camafort, M., Kasiakogias, A., Agabiti‐Rosei, E., Masi, S., Iliakis, P., Bénétos, A., Jeong, J., Lee, H., Muiesan, M. L., Sudano, I., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.12.034 · Cited by 37
Standardized Definitions of Changes in Kidney Function in Trials of Heart Failure
Lala, A., Coca, S. G., Feinman, J., HAMO, C. E., Fiuzat, M., Abraham, W. T., O’Connor, C. M., Lindenfeld, J., Januzzi, J. L., Cavagna, I., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.041 · Cited by 34
Renin-angiotensin-aldosterone system and its relation to hypertension
Miura, S.-I., Matsuo, Y., & Seumatsu, Y. (2025) · Hypertension Research · doi:10.1038/s41440-025-02229-5 · Cited by 33
“In the PARAGON-HF trial, heart failure patients with preserved ejection fraction were randomly assigned to either the SAC/VAL group or the valsartan-only group [31].”
Li, R., Liu, Y., Zhao, Z., Zhang, C., Dong, W., Yu, Q., Gao, J., Gu, F., Carlson, B. E., Beard, D. A., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103462 · Cited by 32
Fu, E. L., Uijl, A., Dekker, F. W., Lund, L. H., Savarese, G., & Carrero, J. J. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.120.007180 · Cited by 35
Phenomapping Heart Failure with Preserved Ejection Fraction Using Machine Learning Cluster Analysis
Galli, E., Bourg, C., Kosmala, W., Oger, E., & Donal, E. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.02.010 · Cited by 35
Heart failure population health considerations
Patel, J. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88673 · Cited by 35
Bachmann, J. C., Baumgart, S. J., Uryga, A., Bosteen, M. H., Borghetti, G., Nyberg, M., & Herum, K. M. (2022) · Cells · doi:10.3390/cells11101657 · Cited by 31
Zhou, H., Peng, W., Li, F., Wang, Y., Wang, B., Ding, Y., Lin, Q., Zhao, Y., Pan, G., & Wang, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.875327 · Cited by 34
“Current studies have found that both SGLT2 inhibitors and Sacubitril/Valsartan can inhibit the renin-angiotensin-aldosterone system (RAAS), causing dilation of afferent glomerular arteriole and efferent arteriole, resulting in a decrease in renal arterial pressure, causing a decrease in renal perfusion and thus a decr…”
BackgroundResultInfluentialManagement of Heart Failure With Reduced Ejection Fraction
Rashid, A. M., Khan, M. S., Fudim, M., DeWald, T. A., DeVore, A. D., & Butler, J. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101596 · Cited by 35
Mentz, R. J., Ward, J. H., Hernandez, A. F., Lepage, S., Morrow, D. A., Sarwat, S., Sharma, K., Solomon, S. D., Starling, R. C., Velazquez, E. J., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.02.001 · Cited by 31
Self-citationButt, J. H., Lu, H. Y., Kondo, T., Bachus, E., de Boer, R. A., Inzucchi, S. E., Jhund, P. S., Kosiborod, M., Lam, C. S. P., Martínez, F. A., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3000 · Cited by 33
Self-citationFerreira, J. P., Vasques‐Nóvoa, F., Saraiva, F. A., Oliveira, A., Almeida, J., Batista, A. B., Barbosa, A., Ferreira, A. F., Costa, C., Diaz, S. O., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.05.033 · Cited by 30
Self-citationCentral Adiposity or Hypertension
Packer, M., Butler, J., Lam, C. S. P., Zannad, F. M., Vaduganathan, M., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.036 · Cited by 32
“132,133 However, these meaningful decreases in systolic blood pressure in both trials were accompanied by only modest effects (11%-13”
Self-citationOn the search for the right definition of heart failure with preserved ejection fraction
Kapłon‐Cieślicka, A., Kupczyńska, K., Dobrowolski, P., Michalski, B. W., Jaguszewski, M. J., Banasiak, W., Burchardt, P., Chrzanowski, Ł., Darocha, S., Domienik‐Karłowicz, J., et al. (2020) · Cardiology Journal · doi:10.5603/cj.a2020.0124 · Cited by 34
Raffaello, W. M., Henrina, J., Huang, I., Lim, M. A., Suciadi, L. P., Siswanto, B. B., & Pranata, R. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.20 · Cited by 37
Myhre, P. L., Selvaraj, S., & Solomon, S. D. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000852 · Cited by 31
Self-citationFu, S., Xu, Z., Lin, B., Chen, J., Huang, Q., Xu, Y., Xu, A., Chen, Y., & Tang, Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.657067 · Cited by 32
“Conversely, the PARAGON-HF trial, a recent, promising double blind randomized study in 4,822 patients with HFpEF, the results showed that sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for HF and death from CV causes among patients with HF and an EF of 45% or higher (16).”
BackgroundResultSeverino, P., D’Amato, A., Prosperi, S., Fanisio, F., Birtolo, L. I., Costi, B., Netti, L., Chimenti, C., Lavalle, C., Maestrini, V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147650 · Cited by 32
“However, it suggested possible benefit among woman and patients with a left ventricular ejection fraction between 45–57% [178].”
BackgroundFurberg, J. K., Rasmussen, S., Andersen, P. K., & Ravn, H. (2021) · Pharmaceutical Statistics · doi:10.1002/pst.2167 · Cited by 32
“For PARADIGM, a recurrent composite heart failure hospitalisation and CV death endpoint and a recurrent heart failure hospitalisation endpoint were analysed using a LWYY model.6 The same was done for PARAGON-HF.3 For CHARM-Preserved, a recurrent composite heart failure hospitalisation and CV death was analysed using a…”
BackgroundMethodInfluentialXiong, B., Nie, D., Qian, J., Yao, Y., Yang, G., Rong, S., Zhu, Q., Du, Y., Jiang, Y., & Huang, J. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13677 · Cited by 30
“Data from PARAGON-HF suggested that the mean systolic blood pressure was approximately 5 mmHg lower in sacubitril– valsartan than in valsartan.(31) However, in our meta-analysis, the incidences of hypotension, hyperkalaemia, angioedema, and cough were similar between sacubitril–valsartan and ACEI/ARB groups.”
ResultBayés‐Genís, A., Aimo, A., Metra, M., Anker, S. D., Seferovic, P. M., Rapezzi, C., Castiglione, V., Núñez, J. E., Emdin, M., Rosano, G. M. C., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2542 · Cited by 31
Nyberg, M., & JONES, A. M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.898395 · Cited by 34
Targeting Myocardial Fibrosis—A Magic Pill in Cardiovascular Medicine?
Scridon, A., & Balan, A. I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081599 · Cited by 31
Heart Failure with Preserved Ejection Fraction in Children
Das, B. B., Deshpande, S. R., Venkata, J. A., Shakti, D., Moskowitz, W. B., & Lipshultz, S. E. (2022) · Pediatric Cardiology · doi:10.1007/s00246-022-02960-7 · Cited by 30
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
Jhund, P. S. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.010 · Cited by 33
Self-citationMoghaddam, N., Hawkins, N. M., McKelvie, R. S., Poon, S., Joncas, S. X., MacFadyen, J. R., Honos, G. N., Wang, J., Rojas‐Fernandez, C. H., Kok, M., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.10.013 · Cited by 31
Akiyama, H., Nishimura, A., Morita, N., & Yajima, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111984 · Cited by 32
Novel Perspectives in Chronic Kidney Disease-Specific Cardiovascular Disease
Xu, C., Tsihlis, G., Chau, K., Trinh, K., Rogers, N. M., & Julovi, S. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052658 · Cited by 33
Kaye, D. M., Wolsk, E., Nanayakkara, S., Mariani, J. A., Hassager, C., Gustafsson, F., Møller, J. E., Sunagawa, K., & Burkhoff, D. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.021584 · Cited by 32
“24 Interestingly, the beneficial effect of pulmonary artery pressure monitoring in the CHAMPION trial, which included patients with HFpEF, appeared to be largely related to consequent up-titration of diuretics, 25 suggesting that careful volume modification might exert favorable effects.”
Tyl, B., Lopez Sendon, J., Borer, J. S., Lopez De Sa, E., Lerebours, G., Varin, C., De Montigny, A., Pannaux, M., & Komajda, M. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.119.006720 · Cited by 29
Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF
Rosano, G. M. C., Vitale, C., & Spoletini, I. (2024) · International Journal of Heart Failure · doi:10.36628/ijhf.2023.0058 · Cited by 31
“32) The Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction trial 33) found no mortality or hospitalization benefit of sacubitril/valsartan over valsartan in HFpEF, but did show improvement in measures of cardiac structure and function like left atrial…”
Dewan, P., Shen, L., Ferreira, J. P., Jhund, P. S., Anand, I. S., Chandra, A., Chiang, L., Claggett, B. L., Desai, A. S., Gong, J., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.068774 · Cited by 31
Self-citationMahmood, A., Dhall, E., Primus, C., Gallagher, A. M., Zakeri, R., Mohammed, S. F., Chahal, C. A. A., Ricci, F., Aung, N., & Khanji, M. Y. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae053 · Cited by 31
Akoumianakis, I., & Filippatos, T. D. (2020) · Obesity Reviews · doi:10.1111/obr.13077 · Cited by 33
Nie, D., Xiong, B., Qian, J., Rong, S., Yao, Y., & Huang, J. (2020) · Heart Lung and Circulation · doi:10.1016/j.hlc.2020.10.012 · Cited by 29
Nakamura, T., & Tsujita, K. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.03.004 · Cited by 36
Mahabadi, A. A., Anapliotis, V., Dykun, I., Hendricks, S., Al‐Rashid, F., Lüdike, P., Totzeck, M., & Rassaf, T. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.04.009 · Cited by 29
Distinct pathophysiological pathways in women and men with heart failure
Ravera, A., Santema, B. T., de Boer, R. A., Anker, S. D., Samani, N. J., Lang, C. C., Ng, L. L., Cleland, J. G. F., Dickstein, K., Lam, C. S. P., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2534 · Cited by 32
Self-citationPatel, R. B., Greene, S. J., Xu, H., Alhanti, B., Peterson, P. N., Yancy, C. W., Piccini, J. P., Fonarow, G. C., & Vaduganathan, M. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2729 · Cited by 34
Nakamaru, R., Shiraishi, Y., Sandhu, A. T., Heidenreich, P. A., Shoji, S., Kohno, T., Takei, M., Nagatomo, Y., Nakano, S., Kohsaka, S., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14245 · Cited by 29
Zhang, X., Han, X.-W., Jiang, Y., Wang, Y., He, X.-L., Liu, D., Huang, J., Liu, H.-H., Ye, T., Li, S.-J., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110747 · Cited by 30
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., Comin-Colet, J., Cleland, J., Düngen, H.-D., Goncalvesova, E., Katova, T., Kerr Saraiva, J. F., Lelonek, M., Merkely, B., Senni, M., Shah, S. J., Zhou, J., Rizkala, A. R., Gong, J., Shi, V. C., & Lefkowitz, M. P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Anand, Inder S.
- Ge, Junbo
- Lam, Carolyn S.P.
- Maggioni, Aldo P.
- Packer, Milton
- Pfeffer, Marc A.
- Pieske, Burkert
- Redfield, Margaret M.
- Rouleau, Jean L.
- Zannad, Faiez
- Zile, Michael R.
- Desai, Akshay S.
- Claggett, Brian
- Jhund, Pardeep S.
- Boytsov, Sergey A.
- Cleland, John
- Düngen, Hans-Dirk
- Lelonek, Małgorzata
- Senni, Michele
- Shah, Sanjiv J.
- Zhou, Jingmin
- Rizkala, Adel R.
- Gong, Jianjian
- Shi, Victor C.
- Lefkowitz, Martin P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1609-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971294569
- Cited by
- 2,430
- References
- 25
- Citations by year
- 2026: 258 · 2025: 296 · 2024: 338 · 2023: 361 · 2022: 414 · 2021: 385 · 2020: 318 · 2019: 55
- FWCI
- 211.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- sacubitril/valsartan, valsartan, angiotensin receptor-neprilysin inhibition, heart failure with preserved ejection fraction, heart failure hospitalization, cardiovascular mortality, NYHA functional class, renal function, Kansas City Cardiomyopathy Questionnaire, natriuretic peptides, structural heart disease, drug safety, adverse events, anemia of chronic kidney disease, hyperkalemia
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angioedema, Biphenyl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Quality of Life, Sex Factors, Stroke Volume, Tetrazoles, Neprilysin, Single-Blind Method, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.